Urinary F2-Isoprostanes as a Biomarker of Reduced Risk of Type 2 Diabetes

被引：30
作者：
Il'yasova, Dora [1 ]
Spasojevic, Ivan [1 ]
Base, Karel [1 ]
Zhang, Haoyue [2 ]
Wang, Frances [1 ]
Young, Sarah P. [2 ]
Millington, David S. [2 ]
D'Agostino, Ralph B., Jr. [3 ]
Wagenknecht, Lynne E. [3 ]
机构：
[1] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27708 USA
[2] Duke Univ, Med Ctr, Dept Pediat Med Genet, Durham, NC USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA
来源：
DIABETES CARE | 2012年 / 35卷 / 01期
基金：
美国国家卫生研究院;
关键词：
OXIDATIVE STRESS;
D O I：
10.2337/dc11-1502
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OBJECTIVE We have previously reported evidence of an inverse association between a urinary F-2-isoprostane and type 2 diabetes risk in a pilot case-control study nested within the Insulin Resistance Atherosclerosis Study (IRAS). Here, we report the results from the study extended to the entire IRAS cohort. RESEARCH DESIGN AND METHODS This prospective study included 138 incident type 2 diabetes case and 714 noncase subjects. Four F-2-isoprostanes (iPF2 alpha.-III; 2,3-dinor-iPF2 alpha-III; iPF2 alpha-VI; and 8,12-iso-iPF2 alpha-VI) were assayed in baseline urine samples using liquid chromatography tandem mass spectrometry. RESULTS Three F2-isoprostanes showed significant inverse associations with type 2 diabetes risk: the adjusted odds ratios were 0.52 (95% Cl 0.39-0.67), 0.56 (0.42-0.73), 0.62 (0.48-079), and 0.91 (0.72-1.12) for iPF2 alpha-III, 2,3-dinor-iPF2 alpha-III; iPF2 alpha-VI; and 8,12-iso-iPF2 alpha-VI, respectively. CONCLUSIONS Our findings indicate that urinary F-2-isoprostanes are inversely associated with type 2 diabetes risk beyond the traditional risk factors and may be useful in identifying highrisk populations.
引用
收藏
页码：173 / 174
页数：2
相关论文
共 10 条
[1]  
[Anonymous], 1985, DIAB MELL REP WHO ST
[2]   F2-isoprostanes in human health and diseases:: From molecular mechanisms to clinical implications [J].
Basu, Samar .
ANTIOXIDANTS & REDOX SIGNALING, 2008, 10 (08) :1405-1434
[3]   Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes [J].
Il'yasova, D ;
Morrow, JD ;
Wagenknecht, LE .
OBESITY RESEARCH, 2005, 13 (09) :1638-1644
[4]   Prospective association between fasting NEFA and type 2 diabetes: impact of post-load glucose [J].
Il'yasova, D. ;
Wang, F. ;
D'Agostino, R. B., Jr. ;
Hanley, A. ;
Wagenknecht, L. E. .
DIABETOLOGIA, 2010, 53 (05) :866-874
[5]   Urinary Biomarkers of Oxidative Status in a Clinical Model of Oxidative Assault [J].
Il'yasova, Dora ;
Spasojevic, Ivan ;
Wang, Frances ;
Tolun, Adviye A. ;
Base, Karel ;
Young, Sarah P. ;
Marcom, P. Kelly ;
Marks, Jeffrey ;
Mixon, Gabriel ;
DiGiulio, Richard ;
Millington, David S. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (06) :1506-1510
[6]   RELATIONSHIP AMONG PERIPHERAL GLUCOSE-UPTAKE, OXYGEN-CONSUMPTION, AND GLUCOSE-TURNOVER IN POSTABSORPTIVE MAN [J].
JACKSON, RA ;
HAMLING, JB ;
BLIX, PM ;
NABARRO, JDN .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 59 (05) :857-860
[7]   Obesity and systemic oxidative stress - Clinical correlates of oxidative stress in the Framingham Study [J].
Keaney, JF ;
Larson, MG ;
Vasan, RS ;
Wilson, PWF ;
Lipinska, I ;
Corey, D ;
Massaro, JM ;
Sutherland, P ;
Vita, JA ;
Benjamin, EJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (03) :434-439
[8]   Association of oxidative stress, insulin resistance, and diabetes risk phenotypes - The framingham offspring study [J].
Meigs, James B. ;
Larson, Martin G. ;
Fox, Caroline S. ;
Keaney, John F., Jr. ;
Vasan, Ramachandran S. ;
Benjamin, Emelia J. .
DIABETES CARE, 2007, 30 (10) :2529-2535
[9]   Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry [J].
Tolun, Adviye A. ;
Zhang, Haoyue ;
Il'yasova, Dora ;
Sztaray, Judit ;
Young, Sarah P. ;
Millington, David S. .
ANALYTICAL BIOCHEMISTRY, 2010, 402 (02) :191-193
[10]  
Wagenknecht Lynne E., 1995, Annals of Epidemiology, V5, P464, DOI 10.1016/1047-2797(95)00062-3
1